Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 8Lymphoma, T-Cell, Cutaneous 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Lymphoma, T-Cell, Peripheral 5Carcinoma, Ovarian Epithelial 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, Follicular 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Kidney Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Turcot syndrome 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × denileukin diftitox × Clear all
NCT01127451 2022-04-13

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Eisai Inc.

Phase 2 Completed
75 enrolled 15 charts
Dermatologic

Melanoma, Neoplasms

NCT01401530 2018-11-23

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Eisai Inc.

Phase 1 Completed
13 enrolled 18 charts
Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, T-Cell, Peripheral

NCT01432483 2015-01-26

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Eisai Inc.

No longer available

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡